There is an enormous body of evidence that supports the contention that many full-blown chronic diseases can be preempted with proactive intervention in the early disease state. While there are many prescription medications for the treatment of disease, what about individuals who are not yet ready for prescription-drug intervention, but are clearly headed for trouble? These people have moderately increased or borderline-high levels of biochemical markers like cholesterol, glucose, etc.

This is the pre-disease stage and is it when physicians and patients have a window of opportunity to preempt disease through use of evidence-based OTx products, like those promoted by PMEDS, before disease become irreversible.

Evidence-based OTx formulations, like those marketed by PMEDS, have their greatest impact as first line therapeutic options for the newly diagnosed because of their proven efficacy and a gentler and virtually non-existent side effect profile.